Clinical trials: Tumor Immune Microenvironment
Multiple Myeloma
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation
This randomized phase II trial compares how well adding XMO2 Filgrastim (Granix) to melphalan before a stem cell transplant works in treating patients with multiple myeloma.
- Trial name
- NCT02112045
- Testing
- Granix, High dose melphalan (HDR), Autologous Stem Cell Transplant (ASCT)
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Washington University School of Medicine
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Vitamin D Deficiency
Nutrition and Body Composition in Acute Lymphoblastic Leukemia
Many adolescents with acute lymphoblastic leukemia (ALL) have been found to have low bone density by the end of treatment. This can lead to long-term suffering in survivors due to poor bone health.
- Trial name
- NCT01317940
- Testing
- Vitamin D and Calcium Citrate
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Los Angeles
Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Background: Studies conducted at the National Cancer Institute suggest that certain chemotherapy drugs may be more effective if given by continuous infusion into the vein rather than by the standard method of rapid intravenous…
- Trial name
- NCT01030900
- Testing
- Campath, Rituximab, EPOCH
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
This phase II trial studies the best dose and effect of tocilizumab in combination with atezolizumab and stereotactic radiation therapy in treating glioblastoma patients whose tumor has come back after initial treatment…
- Trial name
- NCT04729959
- Testing
- Atezolizumab, Biospecimen Collection, Conventional Surgery
- Where
- 110 sites in United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
UARK 2003-33, Total Therapy III
There have been two previous Total Therapy studies for multiple myeloma (MM) at the Myeloma Institute for Research and Therapy (MIRT): Total Therapy I (from 1989 through 1994) and Total Therapy II (from 1996 to 2004).
- Trial name
- NCT00081939
- Testing
- Velcade, Thalidomide
- Where
- United States
- Volunteers
- 303 people
- Sponsor
- University of Arkansas